According to Zacks, “Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for patients with sleep disordered breathing comprising mild-to-moderate obstructive sleep apnea. Vivos Therapeutics Inc. is based in Highlands Ranch, Colorado. “
Separately, Craig Hallum cut their price objective on shares of Vivos Therapeutics to $5.00 and set a na rating on the stock in a research report on Tuesday, May 17th.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Cambridge Investment Research Advisors Inc. increased its stake in Vivos Therapeutics by 60.0% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 19,200 shares of the company’s stock valued at $43,000 after buying an additional 7,200 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Vivos Therapeutics in the 1st quarter valued at $29,000. Perkins Capital Management Inc. increased its stake in Vivos Therapeutics by 10.3% in the 1st quarter. Perkins Capital Management Inc. now owns 150,050 shares of the company’s stock valued at $402,000 after buying an additional 14,000 shares during the last quarter. Jane Street Group LLC acquired a new stake in Vivos Therapeutics in the 3rd quarter valued at $60,000. Finally, National Asset Management Inc. increased its stake in Vivos Therapeutics by 46.9% in the 3rd quarter. National Asset Management Inc. now owns 50,987 shares of the company’s stock valued at $206,000 after buying an additional 16,269 shares during the last quarter. 9.81% of the stock is currently owned by institutional investors and hedge funds.
Vivos Therapeutics Company Profile (Get Rating)
Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.
- Get a free copy of the StockNews.com research report on Vivos Therapeutics (VVOS)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.